|
The Health Economics Methods Advisory (HEMA) announced a new research topic this week: an assessment of approaches to evaluating, presenting, and communicating uncertainty in economic evaluations.
Mark Sculpher, PhD, Chair of the HEMA Working Group, explained: “Uncertainties in economic evaluation can come from a range of sources, including small sample sizes, limitations in the available evidence, and assumptions used in the modeling. There are both established tools and new methods for quantifying these uncertainties; our goal is not only to review those methods, but also to recommend the best ways to use those tools to make better decisions about new medicines.”
HEMA plans to publish the final report in the first half of 2027. We look forward to learning more!
(Separately, on May 14th, ICER will host a virtual public meeting to discuss oveporexton, a treatment for narcolepsy type 1. An independent appraisal committee will review the findings of ICER's Evidence Report, hear further testimony from stakeholders, and deliberate on the treatment’s comparative clinical effectiveness, benefits beyond health, and long-term value for money. Register here.)
|